Materials and Methods: 50 eyes of 43 patients with diabetic maculapathy that underwent single dose intravitreal bevacizumab (Avastin,) injection were analyzed retrospectively. Best corrected visual acuity (BCVA) was evaluated according Snellen chart . Foveal thickness was measured with optic coherence tomography (OCT) before and 1, 3 and 6 months after injection. Patients were compared in terms of BCVA and foveal thickness at 1st, 3th and 6th months.

Results: Mean follow-up period was 9.08±2.26 (6-15) months. Mean BCVA was determined as 0.29±0.19 before injection, 0.42±0.22 at 1st month, 0.37 ± 0.2 at 3th month and 0.33±0.18 at 6th month after injection. The improvement in visual acuity at 1st and 3th months were found statistically significant (p<0.01, p<0.01). The improvement in visual acuity at 6th month was not statistically significant (p=0.094). Mean foveal thickness was measured as 413.8±136 μm before injection, 309.9±103 μm, 330.8±123 μm and 369.3±156 μm at 1st, 3th and 6th months, respectively. The difference between preinjection and postinjection mean foveal thickness changes was founs statistically significant (p<0.01, p<0.01, p<0.02).

Conclusion: Effect of single dose intravitreal bevacizumab injection on visual acuity and foveal thickness in therapy of diabetic retinopathy with macular edema was reached the highest value in first month. The efficacy of injection are sustained for six months, although reduced. Keywords : Diabetic macular edema, intravitreal, bevacizumab